Boston Scientific (NYSE:BSX) has announced an acquisition of Axonics (NASDAQ:AXNX) that is expected to be completed 2024-H1.
Under the terms of the agreement, Boston Scientific has agreed to give Axonics $3.70 billion in cash in exchange for AXNX stock.
About The Companies Involved
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation ...